Skip Nav Destination
Issues
1 June 2018
-
Cover Image
Cover Image
ABOUT THE COVER
Cover image adapted from Figure 1A, published in Osborn et al., beginning on page 1251. Here, molecular modeling has been used to generate a three-dimensional (3D) representation of a chemically modified, cholesterol-conjugated, self-delivering siRNA (hsiRNA). hsiRNAs are capable of rapid membrane association via cholesterol intercalation into lipid bilayers. These modifications enable siRNA delivery into cells that are notoriously difficult to transfect, including neurons, astrocytes, and as shown in this manuscript, primary human gliomas. Key—Dark purple: cholesterol; light purple: linker; purple: terminal 5′-phosphate; red: phosphorothioate backbone substitutions; black: 2′-O-methyl nucleotide; gray: 2′-fluoro nucleotide. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel; Manikandan Periyasamy; Georgina P. Sava; Alexander Bondke; Brian W. Slafer; Sebastian H. B. Kroll; Marion Barbazanges; Richard Starkey; Silvia Ottaviani; Alison Harrod; Eric O. Aboagye; Laki Buluwela; Matthew J. Fuchter; Anthony G. M. Barrett; R. Charles Coombes; Simak Ali
Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
Giovanni E. Lombardo; Valentina Maggisano; Marilena Celano; Donato Cosco; Chiara Mignogna; Federica Baldan; Saverio M. Lepore; Lorenzo Allegri; Sonia Moretti; Cosimo Durante; Giuseppe Damante; Massimo Fresta; Diego Russo; Stefania Bulotta; Efisio Puxeddu
Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase
Christopher R. Chitambar; Mona M. Al-Gizawiy; Hisham S. Alhajala; Kimberly R. Pechman; Janine P. Wereley; Robert Wujek; Paul A. Clark; John S. Kuo; William E. Antholine; Kathleen M. Schmainda
Large Molecule Therapeutics
Author Choice
IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
Yelena Kovtun; Paul Noordhuis; Kathleen R. Whiteman; Krystal Watkins; Gregory E. Jones; Lauren Harvey; Katharine C. Lai; Scott Portwood; Sharlene Adams; Callum M. Sloss; Gerrit Jan Schuurhuis; Gert Ossenkoppele; Eunice S. Wang; Jan Pinkas
Cancer Biology and Translational Studies
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer
Nicholas Forsythe; Alaa Refaat; Arman Javadi; Hajrah Khawaja; Jessica-Anne Weir; Heba Emam; Wendy L. Allen; Frank Burkamp; Vlad Popovici; Puthen V. Jithesh; Claudio Isella; Melissa J. Labonte; Ian G. Mills; Patrick G. Johnston; Sandra Van Schaeybroeck
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients
J. Andrew Livingston; Wei-Lien Wang; Jen-Wei Tsai; Alexander J. Lazar; Cheuk Hong Leung; Heather Lin; Shailesh Advani; Najat Daw; Janice Santiago-O'Farrill; Mario Hollomon; Nancy B. Gordon; Eugenie S. Kleinerman
Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial
Vasiliki Pelekanou; William E. Barlow; Zeina A. Nahleh; Brad Wasserman; Ying-Chun Lo; Marie-Kristin von Wahlde; Daniel Hayes; Gabriel N. Hortobagyi; Julie Gralow; Debu Tripathy; Peggy Porter; Borbala Szekely; Christos Hatzis; David L. Rimm; Lajos Pusztai
Author Choice
BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors
Camilla Stagni; Carolina Zamuner; Lisa Elefanti; Tiziana Zanin; Paola Del Bianco; Antonio Sommariva; Alessio Fabozzi; Jacopo Pigozzo; Simone Mocellin; Maria Cristina Montesco; Vanna Chiarion-Sileni; Arcangela De Nicolo; Chiara Menin
Models and Technologies
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.